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There is a great need of broaden look on stability tests of active pharmaceutical
ingredients (APIs) in comparison with current requirements contained in pharmacopeia.
By usage of many modern analytical methods the conception of monitoring the changes
of APIs during initial stage of their exposure to harmful factors has been developed. New
knowledge must be acquired in terms of identification of each degradation products,
especially volatile ones. Further research as toxicology prediction during in silico studies
of determined and identified degradation products is necessary. In silico methods
are known as computational toxicology or computer-assisted technologies which
are used for predicting toxicology of pharmaceutical substances such as impurities
or degradation products. This is a specialized software and databases intended to
calculate probability of genotoxicity or mutagenicity of these substances through a
chemical structure-based screening process and algorithm specific to a given software
program. Applying of new analytical approach is proposed as the usage of PAT tools,
XRD, HS-SPME GC-MS/MS, LC-MS/MS for stability testing. Described improvements
should be taken into account in case of each drug existing already in the market as well
as being implemented as new one.
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INTRODUCTION
Scientific achievements and innovations play an increasing role in the European economy.
“Union of innovation” is one of the seven main initiatives planned within the strategy “Europe
2020” for the creation of an intelligent and balanced economy (European Commission –
http://ec.europa.eu/education/policy/strategic-framework/index_en.htm). The concept is mainly
to project, develop, produce, and utilize innovative products, industrial processes, and services
which are more efficient than those of today. They should effect an improvement in quality of
life, as well as help maintain the competitiveness of the European Union (EU) in world markets.
This innovation policy is therefore at the nexus of policies concerning research, technological
development, and industry.
The EU endeavors to provide society with high quality information about the safety and efficacy
of manufactured medicinal products. In turn, the development of pharmaceutical sciences in
recent decades has allowed us to obtain reliable data concerning the quality of drugs. The quality
of active pharmaceutical ingredients (APIs) must be determined during the development of the
conceptual composition and formulation of finished medicinal products, which, besides being
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therapeutically effective, should also be safe for patients.
Evaluation of the quality of APIs is associated with periodic
monitoring of the medicinal substance’s state, starting from its
synthesis and continuing up to its use in the final medicinal
product. The first and pivotal quality parameter, without
which the medicinal effects of an API cannot be evaluated, is
confirmation of substance’s identity, i.e., the determination of its
real chemical structure and its physical form. The purity and
stability of an API is also continuously verified. Quality control
is one of the most important issues in pharmaceutical studies,
in particular in the case of substances that are chemically and
physically labile; it is an unceasing challenge for scientists and
innovators.
The pharmaceutical quality of APIs is evaluated according
to standards and safety requirements developed by many
organizations and agencies, including the ICH (International
Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use) which was
formed in 1991; WHO (World Health Organization), created
in 1948; United States FDA (Food and Drug Administration),
initiated in 1906; and the EMA (European Medicines Agency),
which started its activity 20 years ago as EMEA (European
Agency for the Evaluation of Medicinal Products).
CURRENT GUIDELINES AND STABILITY
TESTING
Current guidelines concerning quality evaluation of substances
involved in medicinal products concentrate on verification of
API stability through determination by particular tests, for
which methods are prescribed (ICH Q1A, 1993), as well as on
the determination of the presence and quantities of impurities
(ICH Q3A, 1994). Researchers investigate different paths of
potential degradation of APIs, they evaluate the speed of changes
occurring under the influence of different factors, and they
assess the possibilities for implementation of stabilizers and
ways of protecting labile substances with confirmed therapeutic
efficacy. The criteria for management of stability tests as well
as the determination and classification of impurities were
developed in the early 1990s, but our understanding of the
problems of API stability has remained the same since the early
1950s.
The process of evaluation of pharmaceutical stability is
composed of different tests, which should determine whether
the API is chemically and physically stable. By definition,
stability is a state in which the degradation of the API does
not occur under the influence of particular factors (Waterman
and Adami, 2005). The factors which are recommended by
ICH for assessment in stability tests are humidity, temperature,
pH, the presence of oxidizing agents, and the influence of
light (ICH Q1A, 1993, 2003). The most important stability
tests of APIs are so called stress tests, which assume excessive,
intense exposure to the action of the factors mentioned above,
in individual ways for different APIs. When the chemical
stability of APIs is considered, the effects of chemical reactions
of the API are evaluated, mainly: hydrolysis in conditions
of increased humidity, oxidation in the presence of oxygen
or hydrogen peroxide, isomerization, hydration, dimerization,
or decarboxylation. Photostability tests are characterized by
particular specificity and are an integral part of stability tests
that are included in standard ICH Q1A (1993). It is worth
noting that the concept of photodegradation is related not only
to changes in the structure of the API under the influence of
light, but also to the occurrence of free-radical processes, energy
transfer, or even luminescence, which may lead to unexpected
and atypical results, especially in the solid state (Glass et al.,
2004). Although the guidelines were established in 1996, data
obtained are still characterized by diversity of the source of
irradiation used, as well as by latitude in the irradiation time
dependent on the equipment used. There are no guidelines which
consider the protection of photolabile substances (Alsante et al.,
2014).
The testing of APIs in the environments of high relative
humidity, increased temperature, very low or high pH, and
exposure to high-intensity electromagnetic radiation from the
UV-Vis range may cause significant loss of the API, but above
all they initiate the formation of degradation products, which
are regulated by other guidelines concerning impurities. An
advantage of stress tests is that they determine the reactivity
of the substance analyzed, as well as the mechanism of its
degradation, which provides valuable information used in the
succeeding stages of drug formulation technology, especially
during manufacturing. These data may also be used to protect
the environment around pharmaceutical factories, for example,
photodegradation processes may be used for the protection of
groundwater. It is worth noting that stress tests may lead to
the formation of different products depending on the stage
of the degradation reaction, similar to the case during free-
radical reactions where the phases initiation, propagation and
termination are significantly different. Therefore, it is very
important to monitor the state of an API and the products
formed over different time intervals. Most commonly, stress tests
establish from 5 to 30% loss of APIs (Reynolds et al., 2002; Alsante
et al., 2014).
Another issue connected with the evaluation of API stability
is physical stability. During stability tests, physical changes in
substances may occur, such as change of polymorphic form
(Yoshioka and Aso, 2007), mobility of an amorphous form
(Chieng et al., 2011), or phase transition (Brittain et al., 1991).
Where an API is unstable in stress tests, degradation products
are formed, which are included in the group of so called
“specific impurities” of the API. According to ICH, an impurity
is any component of the API which is not structurally or
physically defined as that particular API and causes distortion
of its purity. Impurities are divided into three types which are
regulated by different guidelines from ICH and pharmacopeias
(ICH Q3A, 1994; European Pharmacopoeia, 2015): the group
of organic impurities consists of substrates from the API
synthesis, intermediates, degradation products, reagents, ligands,
and catalysts; the group of inorganic impurities consists of
reagents, ligands, catalysts, heavy metals, inorganic salts, and
others, such as carbon; residual solvents fall within the third
group.
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LOW CONCENTRATIONS OF
IMPURITIES MUST BE IDENTIFIED
IN SILICO
The determination of impurities in APIs is a consequence of
testing their chemical stability and relates to knowledge of
structure, physicochemical properties, the assay and toxicology
(Carstensen, 1999; Olsen and Larew, 2005; Huynh-Ba, 2008).
The first ICH regulations concerning quantitation limits of
impurities in APIs (ICH Q3A, 1994) were based on the daily dose
of the API taken by the patient, the route(s) of administration
and the time of therapy; they did not anticipate the need for
impurity identification at concentrations <0.1% (ICH Q3B,
2000). In most cases the finished drug product was used for
the quantitative evaluation of impurities, rather than the API
itself. In 2004, a significant change in approach took place.
Apart from lowering the acceptable limits of quantitation of
impurities in APIs and medicinal products which had been
developed earlier by EMEA, action was taken to study their
toxicity in each situation where they are detected in a drug to
estimate their genotoxic properties (EMEA, 2004). Emphasis
was laid on dangerous chemicals that interact with DNA,
such as N-oxides, aromatic rings, aromatic amines, aldehydes,
aromatic nitric groups, and alkyl-N-nitrosamines (McGovern
and Jacobson-Kram, 2006). For example, impurities that
have undergone stricter evaluation are hydrazine derivatives
associated with the medicinal compounds mildronate and
celecoxib. The degradation product 1,1,1-trimethylhydrazinum
bromine was determined using very specific methods, i.e., HILIC
(Liu et al., 1996) or HS-GC-ECD (Sun et al., 2010). Alkyl halides
are another equally toxic group of compounds and are often
volatile; they are particularly monitored in drug substances
such as diltiazem or azasetron where the impurities are the
highly mutagenic benzyl chloride, chloroethyl methyl ether, and
N,N-dimethylaminoethyl chloride (Reddy et al., 2015). Benzene
derivatives such as (S)-4-nitrophenylalanine hydrate and (S)-
methyl-4-nitrophenylalanate hydrochloride, which were found as
impurities of zolmitriptan, have been confirmed to undergo DNA
damaging reactions using UHPLC-MS/MS and LC-MS/MS.
Recently, research demonstrated that a GC technique coupled
with HS-SPME (head-space solid phase microextraction) and a
MS detector allowed the detection and identification of volatile
photodegradation products of ranitidine hydrochloride, such as
acetaldoxime, thiazole, dimethylacetamide, dimethylformamide,
and 5-methylfurfural (Jamrógiewicz and Wielgomas, 2013),
which have hepatotoxic, carcinogenic, and genotoxic
properties.
To minimize risk, the recent ICH M7 guidelines (2014)
adopted as a requirement in stability testing the use of at
least two in silico tools for prediction of toxicity, genotoxicity,
carcinogenicity, and allergenicity on the basis of chemical
structure and specialized knowledge. Some computer techniques
have been accepted for use to meet such requirements. There are
specialized pieces of software and databases intended to calculate
the probable toxicity of substances through chemical structure-
based screening processes and software specific algorithms. It
has been proposed that the lowest possible quantitation limit of
impurities should be enforced in cases of the predicted presence
of a genotoxic substance formed from an API (Dow et al.,
2013). Generation of new criteria concerning impurities is a
great challenge, because they make it necessary to determine
in a precise way the rate of formation of degradation products
in a genotoxic class from the guidelines Q3A and Q3B
(ICH M7, 2014) at levels <0.1%. Examples of in silico tools
are QSAR (quantitative structure-activity relationships), which
enables the estimation of the connection between a structure,
the properties resulting from it and the toxic activity of the
chemical substance, and DEREK (deductive estimation of risk
from existing knowledge).
OLDER GENERATION APIs – THE NEED
FOR NEW STABILITY STUDIES
Changes to guidelines implemented in the last decade indicate
that the monitoring of structural changes should be conducted
not only for new APIs, but also that older medicinal substances
should be under constant control and monitoring (Olsen and
Larew, 2005). Changes connected with quality control of APIs
are a chance to identify atypical and dangerous impurities
of an API, as well as for the development of methods to
eliminate them (Alsante et al., 2014; Görög, 2015). Review
of older APIs is concerned with the fact that despite the
great quantity of research and stress tests that were performed
on these APIs, the data become incomplete in the light
of new guidelines. Moreover, the development of analytical
methods broadens the possibility for identification of degradation
products of APIs that were not observed before. Therefore,
there is a need to reinvestigate instability effects observed
previously and to evaluate the toxicity of the impurities
determined. Both EMA and WHO underline that nowadays
there is widespread access to analytical tools which enable
assessment of APIs to reach the quantitation limits described in
guidelines. Some available analytical methods, such as liquid/gas
chromatography (LC/GC), are characterized by great specificity
and sensitivity, so enable the determination and identification of
substances at a very low level (McGovern and Jacobson-Kram,
2006; Giordani et al., 2011; EMA, 2012; WHO, 2012; Görög,
2015).
PROTECTION OF CHEMICALLY LABILE
APIs
Where possible, it is worth protecting APIs from harmful
factors to prevent molecular degeneration. Chemical and physical
knowledge obtained over many years allow us to use different
systems which may protect APIs to avoid their degradation,
preventing the formation of impurities. For example, from 1980
to 1990 the protective properties of cyclodextrins and other
supramolecular systems were discovered, and in recent years
many papers have discussed nanotechnological methods of API
stabilization (Baek et al., 2014). Suitable guidelines concerning
this issue have not yet been developed, probably because there
is great heterogeneity in the properties of labile molecules,
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but conclusions about the measurable benefits of physical and
chemical protection of APIs can be drawn from the papers of
many researchers.
PROCESS ANALYTICAL TECHNOLOGY
IN STABILITY TESTING OF APIs AT THE
EARLIEST TIME POSSIBLE
In 2002, the FDA took action in the area of quality control
as well as the evaluation of pharmaceutical stability. This
concerned all manufacturing steps in which contact between
an API and a potentially harmful factor was possible and
in consequence the formation of degradation products may
occur. From then on, efforts were concentrated on quality
evaluation through the assurance of reliability in monitoring
the technological processes, taking into consideration their
variability and their influence on the quality attributes of
APIs. Procedures were collected in one general initiative,
“Process Analytical Technology” (PAT; FDA, 2003), which covers
integrated chemical, physical, microbiological and mathematical
analysis as well as risk analysis of quality loss. Specialized
systems were implemented for control measurements of the
state of APIs to inform on stability. However, PAT lacks a
requirement to achieve full identification of degradation products
(i.e., impurities according to Pharmacopoeias) that are produced.
Based on FDA documentation, pharmacopeial documentation,
and ICH guidelines related to process control of APIs (ICH
Q9, 2005; ICH Q10, 2008; ICH Q8, 2009), EMEA (2009)
proposed using analytical tools which are fast, non-destructive
alternatives to separation methods such as chromatographic
techniques, that allow assessment of the quality, identity, stability,
and purity of samples containing APIs. Additionally, it was
stressed that traditional analytical methods are no longer
sufficient, mainly due to the inability to study real-time processes.
For this purpose PAT recommends the use of near-infrared
spectroscopy (NIR; EMEA, 2009) and Raman spectroscopy,
which enable the management of qualitative and quantitative
analysis not only in real manufacturing mode, so on-line, but
also in laboratory mode, at-line, and remotely, in-line. Moreover,
methods supporting PAT, e.g., for the direct evaluation of
stability, were indicated; these methods allow monitoring of
potential changes occurring in solid samples, as well as in
some isolated or synthesized liquid bulk materials, and in
biosynthesized materials such as enzymes and peptides (without
dissolution of the samples).
Roentgenographic methods were included in the group of
tools supporting PAT, for example X-ray diffraction (XRD),
as well as thermoanalytical methods (e.g., differential scanning
calorimetry (DSC), thermogravimetric analysis), and microscopy
(atomic force microscopy, scanning electron microscopy). In
pharmaceutical technology the most important issue is to
confirm the crystallographic structure, or to assess the spatial
conformation of synthesized APIs and excipients, by means of
roentgenographic techniques (Paradowska and Wawer, 2014),
but this became common only recently. On the basis of the
so called “thermal history” of the sample analyzed, information
about the API’s quality may be obtained by means of differential
scanning calorimetry and thermogravimetry. These tools have
great analytical potential for quality evaluation, as well as
for monitoring the state of APIs. Similarly, microscopic
techniques, in connection with spectroscopic techniques like
Raman spectroscopy or fluorescence spectroscopy, with the
possibility of chemical imaging, are useful tools supporting PAT
conceptions.
It can be concluded that API stability assessment is not
only still valid, but expanding in scope. It is important that
pharmaceutical literature emphasizes the need to conduct such
research into new medicinal substances, as well as older
generation products (Olsen and Larew, 2005) where studies
were conducted according to older guidelines using out-of-date
methods.
One reason that new concepts for stability testing should
be considered (Figure 1) is the lack of clear guidelines on
the quality estimation procedure for therapeutic substances
after a short period of exposure to a damaging factor. Direct
stability studies of APIs in the solid, semi-solid or liquid
phase, particularly in the short term, are a new concept for
monitoring API quality. The first steps in degradation of
an API compound are initiation (such as photodegradation)
and propagation; these are dynamic processes that can lead
to a number of degradation pathways of the API molecule.
Moreover, unknown (or previously unrecognized) degradation
compounds produced can be dangerous to humans (e.g.,
cytotoxic, genotoxic, or mutagenic). For example, the scientific
literature and pharmacopeial guidelines do not mention that
attention should be paid to the production of volatile degradation
products of APIs because of their own toxicity profiles. Particular
databases should be developed for each type of preparation or
drug. PAT, as a quality control system including measurement
of stability at the various stages of manufacture of a medicinal
product, fulfills its role for each type of preparation or drug
(orally administrated, injections, and others). However, broadly
considering new guidelines aimed toward the prevention of toxic
degradation products, PAT is not sufficient. Some additional
analytical procedures should be included in stability tests
wherever there is any information about changes in the structure
of a molecule resulting from its sensitivity to any damaging
agents. At the first sign of changes, the resultant impurities
should be researched, their toxicity assessed and action taken to
eliminate them.
To achieve positive, significant improvement of stability
testing, the most important step is to implement a new pathway
to determine the safety of drug substances:
(a) testing of solid, semi-solid or liquid samples of medicinal
substances in terms of exposure to degradation factors such
as high temperature, humidity, and light;
(b) evaluation of changes on the basis of optimized spectral
analysis by FTIR/NIR spectroscopy, DSC, XRD patterns, and
chromatograms from GC-MS and LC-MS/MS;
(c) determination of time wherein the labile drug substance does
not change physically or chemically under the conditions of
exposure;
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FIGURE 1 | Scheme of the new conceptual approach to chemical stability tests of APIs – in this example, applied to tablets.
FIGURE 2 | New analytical workflow concerning different consequences of stability testing of APIs.
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(d) monitoring for the presence of volatile degradation products
in the samples;
(e) quantitative assessment of ongoing changes in the drug
directly in raw materials;
(f) preliminary assessment of the usefulness of the
results obtained compared to available and applicable
pharmacopeial procedures;
(g) initial assessment of patients’ exposure to selected
degradation products of medicinal substances that may be
cytotoxic (in silico modeling);
(h) stability testing of the medicinal product including sensitive
APIs (with toxic degradation compound profiles) according
to the above proposed procedure;
(i) protection and prevention of API degradation in medicinal
products in case of a confirmed degradation profile (for
example, by improved coating, use of capsules vs. tablets or
inclusive complex formation).
It is worth noting that this new analytical procedure, including
the involvement of different techniques and procedures for the
monitoring of stability of APIs, will allow users to cope with
the most difficult research aims and will influence the normative
consequences (Figure 2). The obtaining of information about
changes in the structure of an API under the influence of
destructive factors will became a signal for the creation of new
standards. The aim of evaluation of normative records is to show
permissible levels of newly identified compounds, as well as to
broaden the range of research. The most important normative
consequence is the possibility of publishing a decision about
withdrawal of a particular API, even one which has been used
in therapy, based on new data which are important from the
safety-of-drugs point of view.
Determination of impurities that are described as
pharmacopeial, on which most analytical procedures for the
quality control of APIs and drugs are based, is insufficient
in the light of new requirements. Most importantly, there is
a lack of practical guidelines that indicate how to deal with
determination of specific impurities, including those that are
on the list of the most dangerous compounds with potential
genotoxic activity. Published studies clearly indicate the need
to focus on procedures for the detection, identification, and
elimination of genotoxic substances present simultaneously
with APIs in medicinal products. The first observations of
change must be made on a short timescale (e.g., 0.5 h), for
example in raw material, using validated PAT tools; then,
other methods should be involved to confirm the presence of
and quantify compounds hazardous to the health of patients.
Finally, all activities should aim to eliminate genotoxic impurities
and/or protect the API against degradation. There is a need
to monitor impurities from all ICH classification groups, with
special attention paid to volatile substances. Moreover, the
collection and preparation of samples, especially non-standard
ones, should be covered by obligatory procedures involving
modern analytical tools. The monitoring of the state of a
molecule in different stages of degradation, occurring because
of different chemical reactions, is innovative and has not been
practiced in the past. Exhaustive data about the chemistry of
APIs may be obtained only by carrying out complementary
research. Nowadays, it is a priority to determine the toxicology
of a compound so as to ensure pharmaceutical quality of
the drug in a way that is compatible with the appropriate
standards.
Highlights of this project is also additional aspect, has not been
featured in literature or in FDA or WHO regulations, which has
become a primary objective of proposed research (Jamrógiewicz
and Ciesielski, 2015).
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